Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
V920 Ebola Vaccine in HIV-Infected Adults and Adolescents
NCT03031912Phase 2Completed
- Sponsor
- Canadian Immunization Research Network
- Start
- Aug 2017
- Primary completion
- Mar 2023
- Modality
- Viral Vector Vaccines
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in Ebola virus disease (EVD) comparing Group 1: V920 with Group 2: Placebo (2 arms). Primary endpoints: Number of Participants With Solicited Adverse Events Following V920 Vaccination at 14 days, Number of Participants With Unsolicited Adverse Events Following V920 Vaccination at 42 days and 2 more. Started Aug 2017; status: completed.
02
Drugs
Ebola Zaire vaccine (live, attenuated)
03
Conditions
Ebola virus disease (EVD)
Beyond the preview
Go deeper on NCT03031912.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03031912.